Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further

GMP violations found at API supplier Kyowa Hakko Bio are spilling over into companies using its ingredients to manufacture final drug products, with Astellas Pharma and Kowa forced to curb their shipments for adenosine triphosphate (ATP) medicines and stock-outs expected...read more